<DOC>
	<DOCNO>NCT01403012</DOCNO>
	<brief_summary>Metabolomics systemic psoriasis treatment</brief_summary>
	<brief_title>BOSTRIP : Biomarkers Systemic Treatment Response Psoriasis</brief_title>
	<detailed_description />
	<mesh_term>Psoriasis</mesh_term>
	<criteria>Male female patient age 18 80 year , body weight ≤ 180 kg Dermatological diagnosis psoriasis Initiated therapy TNFαinhibitor agent ( etanercept , adalimumab infliximab ) fumaric acid ester ( FAE ) within scope routine patient care treat physician Signed informed consent patient Patients evidence skin condition would interfere evaluation psoriasis Use systemic antipsoriatic drug steroid , retinoids , methotrexate , cyclosporine within 30 day Visit 1 use FAE biologic agent etanercept , infliximab adalimumab within 12 week prior Visit 1 Patients consider potentially unreliable envisage patient may consistently attend schedule study visit Patients unable complete patient diary complete questionnaire paper Patients condition prior/current treatment , opinion investigator render patient ineligible study schedule Pregnancy breast feed woman Women childbearing potential , defined woman physiologically capable become pregnant unless use effective contraception study . Effective contraception define either : use establish oral , injected implant hormonal</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>To identify clinical metabolomic marker underlie variability response systemic therapy psoriasis</keyword>
	<keyword>To identify metabolomic signature associate psoriasis</keyword>
	<keyword>To identify possible treatment-specific metabolomic signature</keyword>
</DOC>